

Caroline SANZ

Née le 11/12/79 à Alès (Gard)

1 avenue Sans

31300 Toulouse

N° Ordre 31 111825

Tel: +33562213680

csanz@clinique-pasteur.com

N° RPPS 10100072767

Clinique Pasteur Toulouse

Médecin libéral
Membre du Conseil d'Administration



Titres universitaires

- **Diplôme de Docteur en Médecine** 2008
- **Mémoire de DES** en Endocrinologie, Diabétologie et Maladies Métaboliques 2009
- **Chef de clinique-Assistante des hôpitaux** 2009-2011
Service de Diabétologie, Maladies Métaboliques et Nutrition .Pr Hanaire CHU Toulouse
- **Doctorat de Sciences** Epidémiologie clinique 2012
Ecole Doctorale Mathématiques, Informatique, Télécommunications de Toulouse

Titres hospitaliers

- **Interne des hôpitaux de Toulouse** 2004-2009
- **Chef de clinique-Assistante des hôpitaux** 2009-2011
Service de Diabétologie, Maladies Métaboliques et Nutrition .Pr Hanaire CHU Toulouse
- **Praticien attaché des hôpitaux** 2011-2012

Publications

1. Turnin MC, Gourdy P, Martini J Educ@dom Study Group. Impact of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Randomised Multicentre Study. Diabetes Ther. 2021 Jul;12(7):2059-2075. doi: 10.1007/s13300-021-01095-x. Epub 2021 Jun 23.
2. Mounié M, Costa N, Gourdy P, Latorre C **Educ@dom Study Group**. Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study. Diabetes Ther. 2022 Apr;13(4):693-708. doi: 10.1007/s13300-022-01207-1. Epub 2022 Feb 8.

3. Doucet JA, Bauduceau B, Le Floch JP, Verny C; **SFD/SFGG Intergroup** Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes *Diabetes Care*. 2018 Jan;41(1):156-162.
4. Doucet JA, Bauduceau B, Le Floch JP, Verny C; **SFD/SFGG Intergroup**. Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort. *Fundam Clin Pharmacol*. 2016 Feb;30(1):76-81
5. Bordier L, Buyschaert M, Bauduceau B, Doucet J, Verny C, Lassmann Vague V, Le Floch JP; **SFD/SFGG Intergroup**. Predicting factors of hypoglycaemia in elderly type 2 diabetes patients: Contributions of the GERODIAB study. *Diabetes Metab*. 2015 Sep;41(4):301-303
6. Doucet JA, Bauduceau B, Le Floch JP, Verny C; **SFD/SFGG Intergroup**. Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort. *Fundam Clin Pharmacol*. 2016 Feb;30(1):76-81. doi: 10.1111/fcp.12160. Epub 2015 Nov 8.
7. Bauduceau B, Doucet J, Le Floch JP, Verny C; **SFD/SFGG Intergroup and the GERODIAB Group**. Cardiovascular events and geriatric scale scores in elderly (70 years old and above) type 2 diabetic patients at inclusion in the GERODIAB cohort. *Diabetes Care*. 2014;37(1):304-11.
8. Bouhanick B, Meliani S, Doucet J, Bauduceau B, Verny C, Chamontin B, Le Floch JP; **Gerodiab Study Group**. Orthostatic hypotension is associated with more severe hypertension in elderly autonomous diabetic patients from the French Gerodiab study at inclusion. *Ann Cardiol Angeiol (Paris)*. 2014 Jun;63(3):176-82
9. Barreto PD, **Sanz C**, Vellas B, Lapeyre-Mestre M, Rolland Y. Drug treatment for diabetes in nursing home residents. *Diabet Med*. 2014 May;31(5):570-6. doi: 10.1111/dme.12354. Epub 2013 Nov 22
10. **Sanz C**, Ruidavets JB, Sinclair A, Bongard V, Marquié JC, Hanaire H, Ferrières J and Andrieu S. Relationship between markers of insulin resistance, markers of adiposity, HbA1c and cognitive functions in a middle-aged population based sample: the MONA-LISA study. *Diabetes Care* 2013 Jun;36(6):1512-21
11. Doucet J, Le Floch JP, Bauduceau B, Verny C; **SFD/SFGG Intergroup**. GERODIAB: Glycaemic control and 5-year morbidity/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion. *Diabetes Metab*. 2012 Dec;38(6):523-30. doi: 10.1016/j.diabet.2012.07.001. Epub 2012 Oct
12. **Sanz C**, Hanaire H, Andrieu S, Sinclair A and Vellas B. Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer 's disease. The Real.fr cohort. *Diabetic Medicine*. 2012 Apr;29(4):541-8
13. **Sanz C**, Gauthier JF, Hanaire H. Physical exercise for the prevention and treatment of type 2 diabetes. *Diabetes and Metabolism* 2010 Nov;36(5):346-51
14. **Sanz C**, Andrieu S, Sinclair A, Hanaire H and Vellas B. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. *Neurology* 2009;73: 1359-66.
15. **Sanz C**, Vezzosi D, Pigny P, Bennet A, Caron P: Multiple endocrine neoplasia type 2a and germ line C634G RET mutation diagnosed in an 80-year-old patient. *Ann Endocrinol (Paris)* 70:141-144, 2009
16. Coley N, Andrieu S, Gardette V, Gillette-Guyonnet S, **Sanz C**, Vellas B, Grand A: Dementia Prevention: Methodological Explanations for Inconsistent Results. *Epidemiological Reviews* 2008;30:35-66.
17. Gillette-Guyonnet S, Abellan Van Kan A, Andrieu S, Aquino JP, Arbus C, Becq JP, Berr B, Dantoine T, Dartigues F, Ritz P, Robert P, Rolland Y, **Sanz C**, Soto M, Touchon J, Vellas B: Prevention to progression to dementia in the elderly: rationale and proposal for health-promoting memory consultation (an IANA task force). *The Journal of Nutrition, Health & Aging* 12:520-529, 2008

